TPG-backed Pathology Asia invests Australia's Safe Work
TPG Capital Asia’s Pathology Asia platform has continued a regional roll-up strategy with an investment of undisclosed size in a minority stake in Australian drug testing specialist Safe Work Laboratories.
It follows the acquisition in July last year of a portfolio of 39 pathology laboratories across Singapore, Malaysia, and Vietnam from Australian hospital operator Healthscope for A$279 million ($200 million)....
More on Australasia
Latest News
Dymon makes $145m take-private offer for Singapore's Challenger
Dymon Asia Private Equity (DAPE) has submitted a take-private offer for Singapore-listed digital marketing services provider Challenger Technologies that values the company at about S$195 million ($145 million).
General Atlantic, Tencent invest $31m in India’s Byju’s
Indian educational technology provider Byju’s has raised a INR2.14 billion ($31 million) round of funding from existing investors General Atlantic and Tencent Holdings.
GPs bullish on Chinese IPOs - AVCJ Forum
Private equity investors believe it will become easier to take companies public in China as the country steps up the pace of capital markets reform, creating a system that is more in line with international norms.
LPs emphasize self-awareness in China GPs - AVCJ Forum
Chinese GPs that can identify where their strategies might go wrong – and therefore avoid problems before they emerge – are most likely to emerge as winners in a market characterized by rising competition and changing economic circumstances, LPs told...